-
Featured Authors
Patently BIOtech
Archive
- May 2013 (2)
- April 2013 (5)
- March 2013 (2)
- February 2013 (4)
- January 2013 (1)
- December 2012 (2)
- November 2012 (3)
- October 2012 (3)
- September 2012 (3)
- August 2012 (5)
- July 2012 (4)
- June 2012 (7)
- May 2012 (5)
- April 2012 (3)
- March 2012 (4)
- February 2012 (6)
- January 2012 (2)
- December 2011 (2)
- November 2011 (3)
- October 2011 (3)
- September 2011 (5)
- August 2011 (4)
- July 2011 (8)
- June 2011 (16)
- May 2011 (8)
- April 2011 (9)
- March 2011 (14)
- February 2011 (9)
- January 2011 (15)
- December 2010 (7)
- November 2010 (6)
- October 2010 (4)
- June 2010 (1)
- May 2010 (4)
- April 2010 (14)
- March 2010 (4)
- January 2010 (5)
- November 2009 (3)
- October 2009 (1)
- August 2009 (6)
- July 2009 (9)
- June 2009 (9)
- May 2009 (8)
- April 2009 (9)
- March 2009 (9)
- February 2009 (3)
- January 2009 (1)
- November 2008 (1)
Category Archives: Patently BIOtech
Parallel Importation: A Disincentive for Developing World Access to Medicines
Parallel importation serves as a challenge to improving access to medicines in the developing world. Parallel importation occurs when a country imports a product from a 3rd country to take advantage of a cheaper price than what is present for the same product in-country. The imports then directly and unfairly competes with the same product sold by the rights holder on the local market. Unfortunately for those most in need of special access to medicine Read More >
Brazil Patent Policy: At a Crossroads
The Government of Brazil approaches the patent policy crossroads with two ministries wanting to move in opposite directions. In the last few months, both the Brazilian Patent Office (INPI) and the Brazilian Regulatory Authority (ANVISA) issued proposed rules concerning patents and are sifting through public comments to determine how they will deal with biotech patents. A quirk in Brazilian law requires that the health regulatory authority (ANVISA) must provide “prior consent” on the grant of a pharmaceutical patent. Traditionally, Read More >
BIO IP Counsels Committee Conference: Spring 2013 Line-Up
San Diego, California is the next site for the BIO IP Counsels Committee Conference. On March 25, 2013, biotech IP counsel will gather for an event dedicated to providing in-house IP counsel opportunities to learn cutting edge issues, network with their peers, and to enjoy another great location. Here is the session line-up and confirmed speakers with more speaker confirmations to come. Visit BIO’s IP Counsels Committee Conference page to register and learn more. Pre-Conference Read More >
Patently Biotech’s Top 5 Articles of 2012
2012 has been an eventful year for biotech IP issues. Below are the top 5 articles and from Patently Biotech in 2012. Click on the links to read the full articles. 1. The Real Reason Why Salk Refused to Patent the Polio Vaccine A guest writer in a recent article in the Wall Street Journal repeated the oft quoted Jonas Salk statement about his Polio vaccine: “There is no patent. Could you patent the sun?” Many use this statement Read More >
Whole Genome Sequencing and Myriad Supreme Court Case: Nothing to See Here
Bio IT World just published an article stating that the Myriad Supreme Court case will have little to no effect on whole genome sequencing. “As WGS involves determining the sequence of an individual’s entire genome, there is concern in many quarters that WGS could violate essentially every patent covering an isolated human DNA sequence—of which there are thousands. Indeed, this concern has been raised by scholars, policy analysts and lawyers, including before the Federal Circuit Read More >
